Enhancing Access to Lipid-Lowering Therapies and Optimizing Cholesterol Management in Very High-Risk Patients with ASCVD

A panel of clinical pharmacists introduce themselves and discuss how LDL cholesterol target achievement compares with guideline goals for patients with ASCVD who are treated with maximally tolerated statin monotherapy.

Experts on the management of ASCVD discuss clinical practice patterns of high-risk patients and the common reasons for clinicians not intensifying cholesterol treatment.

The panel compares the ACC/AHA cholesterol guidelines with the ESC/EAS guidelines and provides thoughts on how educational initiatives can be improved to increase familiarity and implementation.

Clinical pharmacists discuss how to address key barriers that get in the way of implementing guideline-directed cholesterol treatment.